Semler Scientific, Inc.
25.99-1.23 (-4.52%)
Oct 29, 4:00:00 PM EDT · NasdaqCM · SMLR · USD
Key Stats
Market Cap
393.55MP/E (TTM)
5.70Basic EPS (TTM)
4.56Dividend Yield
0%Recent Filings
8-K
CFO resigns; CEO steps in
Semler Scientific's CFO Renae Cormier resigned on October 16, 2025, effective October 30, to chase another opportunity, prompting the board to tap CEO Dr. Douglas Murphy-Chutorian as interim CFO without extra pay. This shift adds to the company's plate amid its pending merger with Strive, where Bitcoin volatility and integration snags loom large. Leadership overlap could stretch focus thin.
8-K
Semler-Strive merger advances
Semler Scientific filed supplemental disclosures on its pending all-stock merger with Strive, Inc., announced September 22, 2025, where Semler stockholders will receive 21.05 Strive Class A shares per Semler share, pending approvals. Strive, a Bitcoin treasury firm managing $2B in assets, eyes the deal to boost bitcoin holdings and alpha strategies, yet integration risks loom large amid volatile crypto markets. Deal could falter on antitrust hurdles.
8-K
Semler settles DOJ claims
Semler Scientific settled False Claims Act allegations over Medicare reimbursements for its FloChec and QuantaFlo devices, agreeing to pay $29.75 million plus 4.25% interest from April 28, 2025, without admitting wrongdoing. The deal includes a five-year corporate integrity agreement to overhaul sales practices. Revenues face headwinds: Q3 2025 expected at $6.9-$7.5 million, but Q4 could drop at least 50% after a major customer cuts usage October 1. A class action lawsuit now challenges disclosure timing.
8-K
Semler annual meeting outcomes
Semler Scientific's stockholders, at the September 5, 2025 annual meeting, elected William H.C. Chang as Class I director with 6.8 million votes for, while approving executive compensation on an advisory basis and ratifying BDO USA as auditors for 2025. They boosted authorized common shares to 210 million, gaining flexibility for future issuances. Yet preferred stock authorization failed, signaling caution on new equity tools. This mix bolsters governance continuity but highlights investor wariness.
8-K
Q2 earnings and Bitcoin surge
Semler Scientific reported Q2 2025 revenues of $8.2 million, down 43% year-over-year, with an operational loss of $2.1 million offset by an $83.8 million unrealized Bitcoin gain, driving net income to $66.9 million or $5.04 diluted per share. The company added 1,444 Bitcoins in the quarter and 385 more by July 31, boosting holdings to 5,021 valued at $586.2 million and delivering a 31.3% year-to-date BTC yield. It launched CardioVanta subsidiary for heart failure detection while funding Bitcoin buys via a $500 million ATM program that raised $194.3 million net since April. Bitcoin volatility poses ongoing risks.
IPO
Employees
Sector
Industry
BSX
Boston Scientific Corporation
100.30-0.67
HTFL
Heartflow, Inc.
37.52-0.78
MLSS
Milestone Scientific, Inc.
0.43-0.03
NOVT
Novanta Inc.
128.61+0.93
NUWE
Nuwellis, Inc.
3.05-0.05
QDEL
QuidelOrtho Corporation
27.94-0.25
RMSL
RemSleep Holdings, Inc.
0.00+0.00
SENS
Senseonics Holdings, Inc.
7.25+0.05
SERA
Sera Prognostics, Inc.
3.49-0.26
SNWV
SANUWAVE Health, Inc.
30.44-0.60